LUCENTIS Drug Profile

Summary for Tradename: LUCENTIS

High Confidence Patents:	11
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for LUCENTIS
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LUCENTIS

Recent Clinical Trials for LUCENTIS

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Sun Yat-sen University	PHASE2
Fifth Affiliated Hospital, Sun Yat-Sen University	PHASE2
Incepta Pharmaceuticals Ltd	PHASE3

See all LUCENTIS clinical trials

Recent Litigation for LUCENTIS

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
GENENTECH, INC. v. DR. REDDYS LABORATORIES, INC.	2023-11-17
Genentech, Inc. v. Biogen MA Inc.	2023-07-13
Genentech, Inc. v. Centus Biotherapeutics Limited	2020-11-12

See all LUCENTIS litigation

Pharmacology for LUCENTIS

Mechanism of Action	Vascular Endothelial Growth Factor Inhibitors
Established Pharmacologic Class	Vascular Endothelial Growth Factor Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for LUCENTIS Derived from Brand-Side Litigation

These patents were obtained from brand-side disclosures in response to biosimilar applications

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Patent Expiration
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	June 30, 2006	8,574,869	2028-07-08
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	October 13, 2016	10,421,984	2033-09-19
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	March 20, 2018	6,921,659	2023-10-17
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	June 30, 2006	10,112,994	2035-11-05
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	August 10, 2012	6,828,121	2022-07-08
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	March 20, 2018	10,017,732	2034-03-14

2) High Certainty: US Patents for LUCENTIS Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10,829,732	2038-10-04	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	6,716,602	2021-11-01	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	6,921,659	2022-09-12	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	8,574,869	2032-01-19	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	9,220,631	2033-01-25	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	9,914,770	2034-04-28	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for LUCENTIS Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10,004,788	2037-12-21	Patent claims search
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10,016,338	2036-12-20	Patent claims search
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10,016,434	2037-07-18	Patent claims search
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10,047,096	2035-11-23	Patent claims search
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10,052,307	2035-05-08	Patent claims search
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10,100,034	2037-07-25	Patent claims search

International Patents for LUCENTIS

Country	Patent Number	Estimated Expiration
Jordan	P20200175
Australia	3944002
Hungary	E055227
Croatia	P20180673
Denmark	3656373
Japan	2019141053

Market Dynamics and Financial Trajectory for LUCENTIS (Ranibizumab)

Last updated: February 23, 2026

What is the current market position of LUCENTIS?

LUCENTIS (ranibizumab) is a monoclonal antibody fragment approved for several ocular diseases. Since its market launch in 2006 by Novartis, it has established a leading position in wet age-related macular degeneration (AMD), diabetic macular edema (DME), and proliferative diabetic retinopathy (PDR). As of 2022, LUCENTIS generated approximately $2.1 billion in global sales, accounting for roughly 40% of the anti-VEGF market.

How does LUCENTIS compare to competitors?

Product	Manufacturer	Indications	Approved Year	2022 Global Sales (USD millions)	Market Share (2022)
LUCENTIS	Novartis	AMD, DME, PDR	2006	2,100	40%
EYLEA (aflibercept)	Bayer	AMD, DME, PDR	2011	2,800	53%
Beovu (brolucizumab)	Bausch + Lomb	AMD, DME	2019	300	6%

EYLEA commands a higher market share globally due to superior dosing convenience, patient preference, and expanded indications. Beovu, launched more recently, holds a small share driven primarily by early-stage adoption.

What are the key drivers and challenges affecting LUCENTIS’s market trajectory?

Drivers:

• Efficacy and durability: LUCENTIS provides proven efficacy in AMD, especially in patients responsive to anti-VEGF therapy.
• Established safety profile: Over 15 years of use solidifies clinician confidence.
• Broad approved indications: Extends its potential market reach across AMD, DME, and PDR.

Challenges:

• Dosing frequency: LUCENTIS requires monthly injections initially, reducing patient compliance relative to EYLEA, which offers longer dosing intervals.
• Pricing pressures: Generic and biosimilar competition may emerge post-expiry of patents, constraining revenue growth.
• Emerging therapies: Longer-acting agents, gene therapies, and combination drugs threaten continued dominance.

How are patent protections and regulatory pathways influencing future revenue?

LUCENTIS’s primary patent expired in Europe in 2020 and in the U.S. in 2023, allowing biosimilars to enter the market. The biosimilar Sandoz’s product secured FDA approval in late 2022 but launched in the market in early 2024. The entry of biosimilars is projected to cut LUCENTIS’s revenue by 20-30% within the next 2-3 years.

Regulatory filings for new formulations or delivery methods, such as sustained-release implants, could extend patent life or create new revenue streams.

What are the revenue prospects based on current market trends?

Projection models suggest:

• 2023-2025: Revenue could decline by 10-15% due to biosimilar competition.
• 2025-2030: LUCENTIS’s sales could stabilize, reaching approximately $1.2 billion annually, if Novartis introduces improved formulations or expands indications.
• Long-term: Innovative delivery methods or combination therapies could offset revenue decline, but these are still in R&D phases.

How will manufacturing and cost structures influence profitability?

LUCENTIS’s manufacturing involves complex biologic processes with high costs. Biosimilars typically enter at a 20-30% lower price point, squeezing profit margins. Novartis’s R&D and approval costs for new formulations or indications remain high, but patent expiries and biosimilar entry will increasingly compress profit margins.

What strategic actions should investors consider?

• Monitor biosimilar market entry: Biosimilars could erode up to 50% of LUCENTIS’s market share within 3 years.
• Assess pipeline developments: Watch for approval of sustained-release formulations or combination therapies.
• Evaluate pricing and reimbursement policies: Changes in health policies or payor strategies can impact sales.

Key Takeaways:

• LUCENTIS remains the dominant anti-VEGF for AMD, but faces significant competitive pressures.
• Biosimilar entry expected to reduce revenue by up to 30% by 2025.
• Long-term growth depends on pipeline innovation and expansion into new indications.
• Pricing pressures and manufacturing costs will challenge profitability.
• Strategic focus should balance near-term revenue declines with pipeline and formulation advancements.

FAQs

Q1: When will biosimilars significantly impact LUCENTIS’s market share?
A: Biosimilars are expected to launch in the U.S. in 2024, likely leading to a 20-30% revenue decline within 2-3 years.

Q2: What is the competitive advantage of EYLEA over LUCENTIS?
A: EYLEA offers longer dosing intervals, which improves patient compliance and reduces treatment burden.

Q3: Are there new formulations of LUCENTIS under development?
A: Novartis is exploring sustained-release implants and combination therapies, with some candidates in clinical trials.

Q4: How might regulatory policies influence future sales?
A: Favorable reimbursement policies and approval of biosimilars could accelerate revenue decline; conversely, approval of new formulations could extend product lifecycle.

Q5: What is the long-term outlook for LUCENTIS?
A: Long-term depends on pipeline success, market adaptation, and the ability to innovate delivery methods to counter biosimilar and competition effects.

---

References

[1] Novartis Annual Reports, 2006-2022.
[2] IQVIA, "The Global Use of Medicines," 2022.
[3] FDA and EMA Drug Approvals Database, 2022-2023.
[4] Sandoz Biosimilar Run Rate Estimates, 2022.